Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure

The aim of this pilot study is to evaluate the circulatory safety of treatment with the molecular adsorbents recirculating system (MARS) by determining the effect on systemic hemodynamics of a single MARS treatment in patients with acute-on-chronic liver failure (AOCLF). In eight patients admitted with AOCLF, a single 10-hour MARS treatment was performed. Systemic hemodynamic variables were determined before and during treatment. Bilirubin and urea were monitored as measures of protein-bound and water-soluble toxins. During MARS treatment, mean arterial pressure increased from 67 [plusmn] 9 to 76 [plusmn] 6 mm Hg (P [lt ] .05). Systemic vascular resistance index increased from 757 [plusmn] 134 to 884 [plusmn] 183 dyne [middot] s/cm5/m2 (P [lt ] .05), whereas cardiac index remained constant (5.9 [plusmn] 0.7 v 6.0 [plusmn] 1.1 L/min/m2). No episode of dialysis-induced hypotension was observed. Systemic oxygen consumption remained constant (92 [plusmn] 30 v 93 [plusmn] 11 mL/min/m2). Bilirubin levels decreased from 537 [plusmn] 192 to 351 [plusmn] 106 [mu ]mol/L (P [lt ] .05), and urea levels, from 19.1 [plusmn] 13.9 to 6.7 [plusmn] 5.1 mmol/L (P [lt ] .05). In conclusion, MARS treatment proved safe in critically ill patients with no attributing side effects. (Liver Transpl 2001;7:1034-1039.)